Scolaris Content Display Scolaris Content Display

Medicinal herbs for esophageal cancer

This is not the most recent version

Collapse all Expand all

Abstract

Background

Esophageal cancer is the seventh leading cause of cancer death worldwide. Traditional Chinese medicinal herbs are sometimes used as an adjunct to radiotherapy or chemotherapy for this type of cancer.

Objectives

To assess the efficacy and possible adverse effects of the addition of Chinese medicinal herbs to treatment with radiotherapy or chemotherapy for esophageal cancer.

Search methods

We searched the Cochrane Upper Gastrointestinal and Pancreatic Diseases Group Trials Register, The Cochrane Library, MEDLINE, EMBASE, AMED (Allied and Complementary Medicine Database), CBM (Chinese Biomedical Database), China National Knowledge Infrastructure, the Chinese Cochrane Centre Controlled Trials Register and CISCOM (The Research Council for Complementary Medicine) (up to June 2004). Databases of ongoing trials, the internet and reference lists were also searched.

Selection criteria

Randomised controlled trials comparing the use of radiotherapy or chemotherapy with and without the addition of Chinese medicinal herbs.

Data collection and analysis

At least two review authors extracted data and assessed trial quality.

Main results

Two studies were included. The numbers of participants in these two trials were 42 and 80, 122 in total. Both studies were analysed separately because of the differences in interventions used. Although one study reported a positive result, the majority of outcome measurements from the two studies showed no significant benefit with the addition of Chinese herbal medicines to radiotherapy or chemotherapy. There was statistically significant improvement in quality of life with the additional Huachansu injection, however, no statistically significant improvement was found in short‐term therapy effects, one‐year survival rate or the adverse effect of radiation‐induced esophagitis.

Authors' conclusions

The included studies were of low quality. The results suggest Zhenxiang capsules or Huachansu injection may not improve short‐term therapy effects or one‐year survival rate when used as adjunct treatment to chemo‐ or radiotherapy in the treatment of esophageal cancer. The quality of life may be improved by Huachansu injection. The results suggest that more high‐quality trials on Huachansu injection and other Chinese herbal medicines are needed in the future.

PICOs

Population
Intervention
Comparison
Outcome

The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.

See more on using PICO in the Cochrane Handbook.

Plain language summary

Medicinal herbs for esophageal cancer

Chinese herbal medicines are widely used as adjunct therapy to chemo‐ or radiotherapy in patients being treated for cancer of the esophagus. As yet there is no clear evidence that herbal medicines are effective or not in this role. The authors performed a systematic review of the potential benefits of Chinese herbal medicines by comparing chemo‐ or radiotherapy for esophageal cancer with and without concurrent herbal medicines. From the limited information available, there may be no benefit from different Chinese medicinal herb formulations. Although the Huachansu injection seemed to improve the quality of life, neither taking Zhenxiang capsules during radiotherapy nor additional Huachansu injection to chemotherapy showed evidence of improving the short‐term therapeutic effects or one‐year survival rate.